EC Pulmonology and Respiratory Medicine

Review Article Volume 14 Issue 9 - 2025

The Importance of the Pneumonia Guiding Concept in the Fight against Sepsis

I Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: I Klepikov, MD, Professor, Retired, Renton, WA, USA.
Received: June 23, 2025; Published: August 12, 2025




Sepsis (SS) is currently one of the leading problems of global health. Being a complication of various inflammatory diseases, SS is diagnosed in more than half of cases as a consequence of severe acute inflammation of the lung tissue, often at the very beginning of the disease. Despite such an obvious connection with pneumonia, SS has recently been considered and studied as a separate syndrome. The experience of previous studies and clinical trials indicates that a radical change in conceptual ideas about the uniqueness of the pathogenesis of inflammation in the lungs and the priority of pathogenetic approaches in justifying its treatment opens up opportunities for the prevention of such complications.

 Keywords: Sepsis; Acute Pneumonia; Pathogenesis; Pulmonogenic Shock; Pseudosepsis

  1. “WHO. Sepsis” (2024).
  2. J Hawiger., et al. “New paradigms in sepsis: from prevention to protection of failing microcirculation”. Journal of Thrombosis and Haemostasis10 (2015): 1743-1756.
  3. I Klepikov. “Myths, legends and real facts about acute lung inflammation”. Cambridge Scholars Publishing (2024): 334.
  4. Cilloniz C., et al. “Management of pneumonia in critically ill patients”. British Medical Journal 375 (2021): e065871.
  5. Lin CK., et al. “Serum vascular endothelial growth factor affects tissue fluid accumulation and is associated with deteriorating tissue perfusion and oxygenation in severe sepsis: a prospective observational study”. European Journal of Medical Research 1 (2023): 155.
  6. Olivia Vynn. “Cardiology secrets”. Chapter 41. Adair Edition: 2, illustrated Published by Elsevier Health Sciences (2001): 210.
  7. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archiv - European Journal of Physiology 236 (1935): 206-219.
  8. Richards G., et al. “CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS”. Journal of Intensive Care Medicine 1 (2011): 34-40.
  9. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. Journal of the American Medical Association 8 (2016): 801-810.
  10. Gattinoni L., et al. “COVID-19 pneumonia: pathophysiology and management”. European Respiratory Review 162 (2021): 210138.
  11. Chalmers S., et al. “Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers”. World Journal of Critical Care Medicine 5 (2019): 59-71.
  12. Sinha P., et al. “Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials”. Lancet Respiratory Medicine 11 (2023): 965-974.
  13. Flower L., et al. “Role of inflammasomes in acute respiratory distress syndrome”. Thorax4 (2025): 255-263.
  14. Mackenzie G. “The definition and classification of pneumonia”. Pneumonia (Nathan) 8 (2016): 14.
  15. Huang M., et al. “The pathogenesis of sepsis and potential therapeutic targets”. International Journal of Molecular Sciences 20 (2019): 5376.
  16. Jain V., et al. “Pneumonia Pathology”. In StatPearls StatPearls Publishing: Treasure Island, FL, USA (2022).
  17. Shoar S and Musher DM. “Etiology of community-acquired pneumonia in adults: a systematic review”. Pneumonia 12 (2020): 11.
  18. Ponnuthurai AK., et al. “Etiological and clinical profile of virus-associated community-acquired pneumonia in adults”. Chest Infection6 (2020): A55.
  19. Pickens CI., et al. “Microbiology of severe community-acquired pneumonia and the role of rapid molecular techniques”. Seminars in Respiratory and Critical Care Medicine2 (2024): 158-168.
  20. Prescott HC. “The epidemiology of sepsis”. In: Wersinga WJ, Seymour CW, eds. Handbook of sepsis, Cham, Switzerland: Springer International Publishing (2018): 15-28.
  21. Heneghan C., et al. “Differentiating viral from bacterial pneumonia”. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
  22. Claire Lhommet., et al. “Predicting the microbial cause of community-acquired pneumonia: Can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
  23. Montull B., et al. “Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia”. PLoS ONE 11 (2016): e0145929.
  24. Bozóky G and Ruby E. “Community-acquired pneumonia as a cause of sepsis”. Trends in Medicine 3 (2019): 1-4.
  25. Boëlle PY., et al. “Trajectories of hospitalization in COVID-19 patients: An observational study in France”. Journal of Clinical Medicine 10 (2020): 3148.
  26. Lafon T., et al. “SEPSIGN: early identification of sepsis signs in emergency department”. Internal and Emergency Medicine5 (2024): 1575-1587.
  27. Oran DP and Topol EJ. “Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review”. Annals of Internal Medicine 5 (2020): 362-367.
  28. Klepikov I. “As evidenced by the statistics of the pandemic”. Journal of Virology and Antiviral Research 3 (2020): 006.
  29. Lawrence O Gostin and Gigi K Gronvall. “The Origins of Covid-19 - Why It Matters (and Why It Doesn’t)”. New England Journal of Medicine 25 (2023): 2305-2308.
  30. Fan Chung., et al. “Climate change and air pollution: how healthcare providers can help mitigate the risks to respiratory health”. European Medical Journal2 (2024): 31-41.
  31. Kyriazopoulou E., et al. “BioFire® FilmArray® pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial”. Infectious Diseases and Therapy3 (2021): 1437-1449.
  32. Visseaux B., et al. “Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016”. PLoS One7 (2017): e0180888.
  33. Jia-Hao Zhang., et al. “Optimizing patient outcomes in severe pneumonia: the role of multiplex PCR in the treatment of critically ill patients”. Frontiers in Medicine 11 (2024): 1391641.
  34. World Health Organization. “Antimicrobial resistance” (2023).
  35. Jeremy Hsu. “AI discovers new class of antibiotics to kill resistant bacteria”. New Scientist3472 (2024): 12.
  36. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Diseases 7 (2019): 1166-1171.
  37. Lin G L., et al. “Epidemiology and immune pathogenesis of viral sepsis”. Frontiers in Immunology 9 (2018): 2147.
  38. JP Metlay., et al. “Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
  39. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 6 (2023): 615-632.
  40. De Backer D., et al. “Challenges in the management of septic shock: a narrative review”. Intensive Care Medicine 4 (2019): 420-433.
  41. Nuala J Meyer and Hallie C Prescott. “Sepsis and Septic Shock”. New England Journal of Medicine 22 (2024): 2133-2146.
  42. R Gauer., et al. “Sepsis: Diagnosis and management”. American Family Physician7 (2020): 409-418.
  43. Damiani E., et al. “Microcirculation-guided resuscitation in sepsis: the next frontier?” Frontiers in Medicine (Lausanne) 10 (2023): 1212321.
  44. Guarino M., et al. “2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department”. Journal of Clinical Medicine 9 (2023): 3188.
  45. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): 808-810.
  46. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy 11 (2020): 3386-3390.
  47. Attaway A H., et al. “Severe covid-19 pneumonia: pathogenesis and clinical management”. British Medical Journal 372 (2021): n436.
  48. Li X., et al. “Molecular immune pathogenesis and diagnosis of COVID-19”. Journal of Pharmaceutical Analysis 2 (2020): 102-108.
  49. Mehta P., et al. "COVID-19: consider cytokine storm syndromes and immunosuppression". Lancet10229 (2020): 1033.
  50. Baral R., et al. “Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis”. JAMA Network Open 3 (2021): e213594.
  51. Pratik Sinha. “Severe viral lower respiratory tract infections pose a significant burden on patients and healthcare systems”. Respir AMJ.1 (2023): 26-35.
  52. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 10229 (2020): 1054-1062.
  53. Viasus D., et al. “Early, short and long-term mortality in community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 5.
  54. Szakmany T., et al. “The 'analysis of gene expression and biomarkers for point-of-care decision support in Sepsis' study temporal clinical parameter analysis and validation of early diagnostic biomarker signatures for severe inflammation and sepsis-SIRS discrimination”. Frontiers in Immunology 14 (2024): 1308530.

I Klepikov. “The Importance of the Pneumonia Guiding Concept in the Fight against Sepsis”. EC Pulmonology and Respiratory Medicine  14.9 (2025): 01-11.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net